Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BYnpj Vaccines

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

  • Paula Freixeiro1
  • Lisa A. Lewis2,3
  • Leonor Sánchez-Busó4,5
  • Magnus Unemo6,7
  • Sunita Gulati3
  • Aline Linder8
  • Jukka Corander9
  • Odile Barbara Harrison10
  • Christina Dold8
  • Simon Harris11,12
  • Christine S. Rollier8,13
  • Sanjay Ram2
1 more authors
  • Calman Alexander MacLennan14,15
15 affiliations
  1. 1Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  2. 2Center for Scientific Review, National Institutes of Health, Bethesda, MD, USA
  3. 3University of Massachusetts, Worcester, MA, USA
  4. 4Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, ISCIII, Madrid, Spain
  5. 5Joint Research Unit 'Infection and Public Health, Institute for Integrative Systems Biology (I2SysBio), FISABIO-University of Valencia, Valencia, Spain
  6. 6Institute for Global Health, University College London, London, UK
  7. 7WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden
  8. 8Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
  9. 9Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
  10. 10Nuffield Department of Population Health, University of Oxford, Oxford, UK
  11. 11Microbiotica, Cambridge, UK
  12. 12Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
  13. 13School of Biosciences, University of Surrey, Guildford, UK
  14. 14Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. [email protected]
  15. 15Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. [email protected]
Open at sourcePDFDOICite

Abstract

Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31–59% effectiveness. We hypothesised that gonococcal OMV-based vaccines will have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560 lpxL1 − rmp − and FA1090 lpxL1 − rmp − induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254 lpxL1 − rmp − nOMV (P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development.

Related

  1. A candidate gonococcal outer membrane vesicle vaccine which induces persistent immunity in three genetically distinct species of mouse and is similarly immunogenic when formulated with and without aluminium adjuvant
    Ilaria Onofrio, Thomas Belcher, Molly E. Quinn +8
    Frontiers in immunologyPeer-reviewedCC BYFull textMicrobiologyEurope PMCCrossref
  2. Importance of the gonococcal MtrCDE efflux pump system in decreasing bacterial susceptibility to zoliflodacin: implications for future clinical treatment of gonorrhea
    Jacqueline T. Balthazar, Concerta L. Holley, Debayan Dey +2
    mBioPeer-reviewedCC BY 4.0Full textMicrobiologyPMC
  3. Development of an edible vaccine candidate conferring protective efficacy against pneumococcal challenge using conserved PspA epitopes in a murine model
    Shahina Akter, Eva Stoger, Tanjina Akhtar Banu +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textSystems & synthetic biologyCrossref
  4. Finding the Goldilocks zone: modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccine
    Jacob Berrigan, Stephanie R. Monticelli, Pieter Spealman +15
    mBioPeer-reviewedPublisher termsFull textMicrobiologyCrossref
  5. ASOFormer: a Transformer-based model for predicting antisense oligonucleotide efficacy to support therapeutic candidate prioritization
    N. C. Dove, Y. Min, O. Is +3
    bioRxivPreprintCC BYFull textBioinformatics & computational biologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{freixeiro2026preclinical,
  title = {{Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB}},
  author = {Paula Freixeiro and Lisa A. Lewis and Leonor Sánchez-Busó and Magnus Unemo and Sunita Gulati and Aline Linder and Jukka Corander and Odile Barbara Harrison and Christina Dold and Simon Harris and Christine S. Rollier and Sanjay Ram and Calman Alexander MacLennan},
  journal = {npj Vaccines},
  year = {2026},
  month = jun,
  doi = {10.1038/s41541-026-01491-z},
  url = {https://doi.org/10.1038/s41541-026-01491-z},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB
AU  - Paula Freixeiro
AU  - Lisa A. Lewis
AU  - Leonor Sánchez-Busó
AU  - Magnus Unemo
AU  - Sunita Gulati
AU  - Aline Linder
AU  - Jukka Corander
AU  - Odile Barbara Harrison
AU  - Christina Dold
AU  - Simon Harris
AU  - Christine S. Rollier
AU  - Sanjay Ram
AU  - Calman Alexander MacLennan
PY  - 2026
DA  - 2026/06/08
JO  - npj Vaccines
DO  - 10.1038/s41541-026-01491-z
UR  - https://doi.org/10.1038/s41541-026-01491-z
AB  - Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31–59% effectiveness. We hypothesised that gonococcal OMV-based vaccines will have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560 lpxL1 − rmp − and FA1090 lpxL1 − rmp − induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254 lpxL1 − rmp − nOMV (P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development.
SN  - 2059-0105
ER  -